A Clinical Study to Evaluate the Efficacy and Safety of JR-031 in Patients with Epidermolysis Bullosa
Phase of Trial: Phase II
Latest Information Update: 08 Aug 2018
At a glance
- Drugs Remestemcel-L (Primary)
- Indications Epidermolysis bullosa; Skin ulcer
- Focus Therapeutic Use
- 03 Aug 2018 Status changed from active, no longer recruiting to completed.
- 25 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 27 Mar 2017 New trial record